Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Laekna to Start Phase I/II Trials of ATP Inhibitor in US for Lung Cancer

publication date: May 22, 2023

Shanghai Laekna was approved to start US Phase I/II trials of its LAE102 antibody in patients with non-small cell lung cancer (NSCLC). The company describes LAE102 as a potent and selective adenosine triphosphate (ATP) inhibitor with a novel target that regulates tumor growth, immune activation, muscle regeneration and hematopoietic development. Although Laekna is developing several Novartis candidates, Laekna discovered LAE102 itself. It is the company’s first internally-discovered drug candidate to receive IND clearance. Novartis has made an investment in Laekna, and it has in-licensed three candidates from Novartis. Laekna develops novel therapies for cancer and liver fibrosis. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital